💊 의약품 A-Z 🧬 표적 🛠 도구 📚 가이드
전체 의약품 약물 분류 치료 영역 부작용
가이드 용어집 연대표
비교 약물 체내 여정 약물 계열
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Rabeprazole

CHEMBL1219 Phase 4 승인됨 Small molecule
Half-Life
1-2 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
359.4 g/mol
LogP
1.9
Phase
4

A proton pump inhibitor that reduces stomach acid production, used to treat gastroesophageal reflux disease, stomach ulcers, and related conditions. It provides relief from heartburn and helps the esophagus heal from acid damage.

분자량

359.4440 g/mol

LogP

1.90

TPSA

96.30 Ų

리핀스키 5의 법칙

통과

치료 영역

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Non-Small Cell Lung Cancer Asthma Insomnia Infectious Disease Gastroesophageal Reflux Disease Non-Alcoholic Fatty Liver Disease Lymphoma Breast Cancer Atrial Fibrillation Prostate Cancer Colorectal Cancer

약물 분류

A — A - Alimentary Tract and Metabolism

작용 기전

Proton pump inhibitor irreversibly inhibiting gastric H+/K+-ATPase with faster onset than omeprazole.

Pharmacokinetics (PK)

Half-Life 1-2 hours

Pharmacodynamics (PD)

기전

Proton pump inhibitor irreversibly inhibiting gastric H+/K+-ATPase with faster onset than omeprazole.

2D 구조

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
COCCCOc1ccnc(C[S+]([O-])c2nc3ccccc3[nH]2)c1C

                

                

                
                

                    
InChI

                    
InChI=1S/C18H21N3O3S/c1-13-16(19-9-8-17(13)24-11-5-10-23-2)12-25(22)18-20-14-6-3-4-7-15(14)21-18/h3-4,6-9H,5,10-12H2,1-2H3,(H,20,21)

                

                

                

                    
                    

                        
Molecular Formula

                        
C18H21N3O3S

                    

                    
                    

                        
HBD / HBA

                        
1 / 6

                    

                    
                    

                        
회전 가능 결합

                        
8

                    

                    
                    
                    

                        
무거운 원자

                        
25

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
자주 묻는 질문

                

                    
                    

                        
                        

                            
A proton pump inhibitor that reduces stomach acid production, used to treat gastroesophageal reflux disease, stomach ulcers, and related conditions. It provides relief from heartburn and helps the esophagus heal from acid damage.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Proton pump inhibitor irreversibly inhibiting gastric H+/K+-ATPase with faster onset than omeprazole.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Rabeprazole: Half-life: 1-2 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Rabeprazole is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Metformin
                            Small molecule
                        
                        
                        
                            Omeprazole
                            Small molecule
                        
                        
                        
                            Pantoprazole
                            Small molecule
                        
                        
                        
                            Lansoprazole
                            Small molecule
                        
                        
                    

                

                

                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1219.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 5029.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
의학적 면책조항

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.